Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | Outcomes following first-line therapy in routine clinical practice in ALCL

Nicolas Martinez-Calle • 14 May 2020
Lymphoma Brentuximab vedotin

Nicolas Martinez-Calle, MD, MSc, Nottingham University Hospitals NHS Trust, Nottingham, UK, discusses outcomes following first-line therapy in routine clinical practice in ALCL in the UK. These data were submitted as an abstract to the BSH 2020 meeting. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nicolas Martinez-Calle

The unmet needs for patients with CLL in the UK and beyond 2:12
The unmet needs for patients with CLL in the UK and beyond
Nicolas Martinez-Calle • 14 Sep 2025
Investigating the impact of interrupting BTKi therapy on vaccine response in patients with CLL 1:53
Investigating the impact of interrupting BTKi therapy on vaccine response in patients with CLL
Nicolas Martinez-Calle • 14 Sep 2025
UNCOVER: evaluating inequalities in the diagnosis and survival of patients with CLL in England 3:04
UNCOVER: evaluating inequalities in the diagnosis and survival of patients with CLL in England
Nicolas Martinez-Calle • 14 Sep 2025
Updates to the CLL treatment guidelines in the UK: continuous and fixed-duration therapy options 2:42
Updates to the CLL treatment guidelines in the UK: continuous and fixed-duration therapy options
Nicolas Martinez-Calle • 14 Sep 2025

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals